NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis $17.30 +0.05 (+0.29%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Pieris Pharmaceuticals Stock (NASDAQ:PIRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pieris Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.10▼$17.4750-Day Range$16.04▼$18.4752-Week Range$6.20▼$23.20Volume4,608 shsAverage Volume5,837 shsMarket Capitalization$22.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Pieris Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScorePIRS MarketRank™: Pieris Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 623rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Pieris Pharmaceuticals.Read more about Pieris Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pieris Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.03% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 2.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.81 Percentage of Shares Shorted2.03% of the float of Pieris Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPieris Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pieris Pharmaceuticals has recently decreased by 2.19%, indicating that investor sentiment is improving. News and Social Media1.6 / 5News SentimentN/A News SentimentPieris Pharmaceuticals has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Pieris Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Pieris Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,311.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.89% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions40.11% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pieris Pharmaceuticals' insider trading history. Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PIRS Stock News HeadlinesPieris Pharmaceuticals (NASDAQ:PIRS) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?October 23, 2024 | americanbankingnews.comAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 2, 2024 | Porter & Company (Ad)Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.comPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, ENV, AFBI on Behalf of ShareholdersAugust 16, 2024 | stockhouse.comSee More Headlines PIRS Stock Analysis - Frequently Asked Questions How have PIRS shares performed this year? Pieris Pharmaceuticals' stock was trading at $14.56 at the beginning of the year. Since then, PIRS shares have increased by 18.8% and is now trading at $17.30. View the best growth stocks for 2024 here. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) posted its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($2.76) earnings per share for the quarter. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 39.71%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals's stock reverse split on Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), General Electric (GE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/14/2024Today11/02/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees140Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($18.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-39.71% Pretax Margin-114.11% Return on Equity-101.29% Return on Assets-65.00% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$20.87 million Price / Sales1.09 Cash FlowN/A Price / Cash FlowN/A Book Value$21.66 per share Price / Book0.80Miscellaneous Outstanding Shares1,320,000Free Float1,203,000Market Cap$22.84 million OptionableOptionable Beta0.67 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PIRS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.